EGFL6 and breast carcinoma: 111In-DOTA-EGFL6 bound to MDA-MB-435 and MDA-MB-468 cells significantly higher than SK-BR-3 or HEK-293 cells, confirming retention of the breast cancer targeting properties of the peptide.